MAPT and Cerebral cortical atrophy: This finding converges with demonstrations that tau progresses along pathways of FC,18-20 and is more closely associated than amyloid-β with disease outcomes such as cortical atrophy and symptomatology,48-51 where tau’s spatial distribution corresponds more directly to clinical phenotypes and patterns of neurodegeneration.